Category - Markets

Roth Capital Partners launched coverage of Sorrento Therapeutics (NASDAQ:SRNE) with a “buy” rating and $15 price target. The stock closed at $7.74 on Friday. Sorrento has a proprietary fully human antibody library...

Roth Capital Partners initiated coverage of Fortress Biotech (NASDAQ:FBIO) with a “buy” rating and $9 price target. The stock closed at $2.97 on Friday. Fortress is dedicated to acquiring, developing and commercializing...

William Blair raised its price target for Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $12 from $9 after the company licensed exclusive worldwide rights to two preclinical cardiovascular programs to Amgen (NASDAQ:AMGN)...

Ladenburg Thalmann has initiated coverage of BioTime (NYSE MKT, TASE:BTX) with a “buy” rating and $6 price target. The stock closed at $3.59 on Thursday. “We view BioTime as roughly halfway through a restructuring...

Roth Capital Partners has initiated coverage of Kiadis Pharma (Euronext Amsterdam and Brussels: KDS) with a “buy” rating and price target of €17. The stock closed at €11.32 on Wednesday. “We believe Kiadis Pharma...

H.C. Wainwright has launched coverage of OncoMed Pharmaceuticals (NASDAQ:OMED) with a “buy” rating and $20 price target. The stock closed at $11.87 on Wednesday. “We believe OncoMed is entering a year of dramatic...

Roth Capital Partners has launched coverage of Fate Therapeutics (NASDAQ:FATE) with a “buy” rating and a target price of $8. The stock closed at $3.18 on Wednesday. Analyst Mark Breidenbach writes that the...

H.C. Wainwright has initiated coverage of Proteon Therapeutics (NASDAQ:PRTO) with a ‘buy” rating and $18 price target. The stock closed at $8.75 on Wednesday. Proteon is developing a novel therapy to help prolong...

Roth Capital Partners raised its price target for Bionomics (ASE:BNO; OTCQX:BNOEF) to (Australian) $2.50 from $1.50 after the company’s Phase 2 BNC210 trial met its primary and secondary endpoints in treating...

Ladenburg Thalmann has launched coverage of Aviragen Therapeutics (NASDAQ:AVIR) with a “buy” rating and $2.50 price target. The stock closed at $1.60 on Tuesday. “We view Aviragen as an emerging small molecule antiviral...